About The Study: The findings of this diagnostic study including 43,000 individuals undergoing hereditary cancer testing demonstrate that the ability to perform RNA sequencing concurrently with DNA sequencing represents an important advancement in germline genetic testing by improving detection of novel variants and classification of existing variants. This expands the identification of individuals with hereditary cancer predisposition and increases opportunities for personalization of therapeutics and surveillance.
Authors: Rachid Karam, M.D., Ph.D., of Ambry Genetics in Aliso Viejo, California, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being released to coincide with presentation at the American Society of Human Genetics 2023 Annual Meeting.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2023.5586?guestAccessKey=da5c4538-0b68-44da-9215-c4a71cf2cf02&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=110423